NCT04718896

A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

A Multicenter, Open-Label, Randomized Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: UCB Biopharma SRL · Industry
• Sex: All
• Age: 12 Years – 17 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).

Conditions

• Moderate to Severe Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	bimekizumab	Study participants will receive subcutaneously administered bimekizumab (BKZ) at pre-specified time points during the study.

Timeline

• Start date: 2021-04-06
• Primary completion: 2025-03-12
• Completion: 2025-03-12
• First posted: 2021-01-22
• Last updated: 2025-03-24

Locations

11 sites across 4 countries: United States, Canada, Germany, Poland

Regulatory

• FDA-regulated drug study